Soleno Therapeutics, Inc.
SLNO
$65.65
-$1.51-2.25%
NASDAQ
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | 32.66M | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 32.66M | -- | -- | -- | -- |
| Cost of Revenue | 696.00K | -- | -- | -- | -- |
| Gross Profit | 31.96M | -- | -- | -- | -- |
| SG&A Expenses | 28.24M | 29.26M | 37.30M | 49.20M | 10.89M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 38.08M | 42.78M | 58.79M | 79.34M | 23.23M |
| Operating Income | -5.42M | -42.78M | -58.79M | -79.34M | -23.23M |
| Income Before Tax | -4.71M | -43.77M | -55.98M | -76.62M | -21.85M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.71M | -43.77M | -55.98M | -76.62M | -21.85M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -4.71M | -43.77M | -55.98M | -76.62M | -21.85M |
| EBIT | -5.42M | -42.78M | -58.79M | -79.34M | -23.23M |
| EBITDA | -4.92M | -42.27M | -58.29M | -78.84M | -22.74M |
| EPS Basic | -0.09 | -0.95 | -1.27 | -1.83 | -0.57 |
| Normalized Basic EPS | -0.04 | -0.55 | -0.79 | -1.13 | -0.33 |
| EPS Diluted | -0.09 | -0.95 | -1.27 | -1.83 | -0.57 |
| Normalized Diluted EPS | -0.04 | -0.55 | -0.79 | -1.13 | -0.33 |
| Average Basic Shares Outstanding | 50.48M | 46.18M | 43.92M | 41.88M | 38.63M |
| Average Diluted Shares Outstanding | 50.48M | 46.18M | 43.92M | 41.88M | 38.63M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |